Alterity Therapeutics Limited

Equities

ATH

AU0000043945

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:05 2024-04-29 am EDT			5-day change	1st Jan Change
0.006 ^AUD	0.00%		+9.09%	-14.29%

Apr. 16	ADRs End Lower, Purple Biotech Ltd. Declines 29%	DJ
Apr. 12	ADRs End Lower, Leju Holdings Ltd. Declines 72%	DJ

Alterity Therapeutics : Presentation to Extraordinary General Meeting

December 28, 2023 at 04:45 pm EST

Presentation to Extraordinary General Meeting

December 29, 2023December 29, 2023Alterity Therapeutics

EGM Presentation 2023

Post navigation

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

Related Posts

Appendix 4C - Q3 FY23 Quarterly Cash Flow Report

April 27, 2023May 23, 2023

Alterity Therapeutics to Participate in Two Upcoming Investor Conferences

November 22, 2021August 16, 2022

Alterity completes Placement Tranche 1 raising $10M

October 23, 2020August 16, 2022

Leave a Reply Cancel reply

Your email address will not be published.Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

Type in the text displayed above

Attachments

Original Link
Original Document
Permalink

Disclaimer

Alterity Therapeutics Ltd. published this content on 29 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 December 2023 21:44:45 UTC.

Latest news about Alterity Therapeutics Limited

ADRs End Lower, Purple Biotech Ltd. Declines 29%	Apr. 16	DJ
ADRs End Lower, Leju Holdings Ltd. Declines 72%	Apr. 12	DJ
ADRs End Higher, Lixiang Education Holding Co. Ltd. Climbs 69%	Apr. 11	DJ
ADRs Close Lower; VIA Optronics AG Declines 30%	Apr. 10	DJ
Top Midday Gainers	Apr. 10	MT
Alterity Therapeutics Receives AU$3.9 Million R&D Tax Refund	Mar. 25	MT
Genetic Technologies Appoints CFO	Mar. 25	MT
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 29	CI
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 30, 2023	Feb. 28	CI
Alterity Therapeutics Raises AU$3.3 Million for Clinical Trials; Shares Fall 20%	Feb. 22	MT
Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	Feb. 06	CI
Alterity Therapeutics Advances Phase Two Multiple System Atrophy Trial Following Committee Recommendation	Feb. 06	MT
Alterity Therapeutics Completes Securities Purchase Plan	Feb. 01	MT
Alterity Dispatches Documents Of Planned Share Sale	Jan. 10	MT
Alterity Therapeutics Concludes Second Tranche of Placement of AU$3.5 Million; Shares Plunge 20%	Jan. 07	MT
Alterity Therapeutics to Raise Up to AU$2 Million Via Share Purchase Plan	Dec. 29	MT
Transcript : Alterity Therapeutics Limited - Shareholder/Analyst Call	Dec. 28
Alterity Therapeutics Names Phillip Hains as Chief Financial Officer	Dec. 21	MT
Alterity Therapeutics Limited Announces CFO Changes	Dec. 21	CI
ADRs End Lower; Evaxion Biotech Declines 27%	Dec. 05	DJ
Transcript : Alterity Therapeutics Limited - Special Call	Dec. 05
Top Premarket Decliners	Dec. 05	MT
ADRs Close Lower; Aslan Pharmaceuticals Declines 17%	Dec. 04	DJ
Sector Update: Health Care Stocks Rise Late Afternoon	Dec. 04	MT
Sector Update: Health Care	Dec. 04	MT

Chart Alterity Therapeutics Limited

Duration

Period

More charts

Company Profile

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Companyâs lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinsonâs disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

Sector

Biotechnology & Medical Research

Calendar

2025-02-26 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALTERITY THERAPEUTICS LIMITED	-14.29%	20.5M
IQVIA HOLDINGS INC.	+2.01%	42.75B
LONZA GROUP AG	+47.58%	41.61B
MODERNA, INC.	+12.20%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.10%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.23%	18.12B
MEDPACE HOLDINGS, INC.	+30.62%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.13%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.11%	11B

Other Biotechnology & Medical Research